MX2018012410A - Metodos para tratar enfermedades inflamatorias. - Google Patents
Metodos para tratar enfermedades inflamatorias.Info
- Publication number
- MX2018012410A MX2018012410A MX2018012410A MX2018012410A MX2018012410A MX 2018012410 A MX2018012410 A MX 2018012410A MX 2018012410 A MX2018012410 A MX 2018012410A MX 2018012410 A MX2018012410 A MX 2018012410A MX 2018012410 A MX2018012410 A MX 2018012410A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- inflammatory diseases
- treating inflammatory
- diseases
- psoriasis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Abstract
Esta invención se refiere generalmente a métodos para el tratamiento de enfermedades relacionadas con IL-23, en particular, enfermedades inflamatorias, tales como psoriasis o artritis psoriásica, que utilizan anticuerpos anti-IL-23A.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662323075P | 2016-04-15 | 2016-04-15 | |
US201662336815P | 2016-05-16 | 2016-05-16 | |
US201662396855P | 2016-09-20 | 2016-09-20 | |
US201662400116P | 2016-09-27 | 2016-09-27 | |
US201762463959P | 2017-02-27 | 2017-02-27 | |
PCT/US2017/027332 WO2017180821A1 (en) | 2016-04-15 | 2017-04-13 | Methods of treating inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018012410A true MX2018012410A (es) | 2019-02-21 |
Family
ID=58633116
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018012410A MX2018012410A (es) | 2016-04-15 | 2017-04-13 | Metodos para tratar enfermedades inflamatorias. |
Country Status (7)
Country | Link |
---|---|
US (2) | US20170298126A1 (es) |
EP (4) | EP3974451A3 (es) |
JP (2) | JP6728392B2 (es) |
AU (1) | AU2017250583A1 (es) |
CA (1) | CA3018794A1 (es) |
MX (1) | MX2018012410A (es) |
WO (1) | WO2017180821A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3081343A1 (en) * | 2017-11-06 | 2019-05-09 | Janssen Biotech, Inc. | Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody |
JP2022523564A (ja) | 2019-03-04 | 2022-04-25 | アイオーカレンツ, インコーポレイテッド | 機械学習を使用するデータ圧縮および通信 |
AR128226A1 (es) * | 2022-01-07 | 2024-04-10 | Prometheus Biosciences Inc | Métodos para tratar enfermedades inflamatorias con una combinación de inhibidores de tl1a e inhibidores de il23 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
RO118524B1 (ro) | 1992-11-13 | 2003-06-30 | Idec Pharmaceuticals Corp San | Metoda pentru tratarea unei tulburari legata de celulele b |
US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
PL1896073T3 (pl) | 2005-06-30 | 2013-08-30 | Janssen Biotech Inc | Przeciwciała anty-IL-23, kompozycje, sposoby i zastosowania |
PL1937721T3 (pl) | 2005-08-25 | 2010-12-31 | Lilly Co Eli | Przeciwciała anty-IL23 |
SG10201402712QA (en) | 2005-08-31 | 2014-08-28 | Merck Sharp & Dohme | Engineered anti-il-23 antibodies |
RS53685B1 (en) | 2005-12-29 | 2015-04-30 | Janssen Biotech Inc. | HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND APPLICATIONS |
US20080311043A1 (en) * | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
EP2059534B1 (en) | 2007-02-23 | 2012-04-25 | Schering Corporation | Engineered anti-il-23p19 antibodies |
LT2635601T (lt) | 2010-11-04 | 2016-10-10 | Boehringer Ingelheim International Gmbh | Antikūnai prieš il-23 |
JP6293120B2 (ja) * | 2012-05-03 | 2018-03-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗IL−23p19抗体 |
JP2017524359A (ja) * | 2014-07-24 | 2017-08-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Il−23a関連疾患の処置に有用なバイオマーカー |
US20160222102A1 (en) * | 2015-02-04 | 2016-08-04 | Boehringer Ingelheim International Gmbh | Methods of treating inflammatory diseases |
-
2017
- 2017-04-13 EP EP21191271.2A patent/EP3974451A3/en active Pending
- 2017-04-13 JP JP2018553424A patent/JP6728392B2/ja active Active
- 2017-04-13 MX MX2018012410A patent/MX2018012410A/es unknown
- 2017-04-13 US US15/486,448 patent/US20170298126A1/en not_active Abandoned
- 2017-04-13 WO PCT/US2017/027332 patent/WO2017180821A1/en active Application Filing
- 2017-04-13 EP EP19176173.3A patent/EP3560956A3/en not_active Withdrawn
- 2017-04-13 EP EP17719786.0A patent/EP3443005A1/en not_active Withdrawn
- 2017-04-13 CA CA3018794A patent/CA3018794A1/en active Pending
- 2017-04-13 EP EP20182861.3A patent/EP3744733A3/en not_active Withdrawn
- 2017-04-13 AU AU2017250583A patent/AU2017250583A1/en active Pending
-
2019
- 2019-12-21 US US16/724,225 patent/US20200308271A1/en active Pending
-
2020
- 2020-07-01 JP JP2020113955A patent/JP2020172508A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3443005A1 (en) | 2019-02-20 |
EP3744733A3 (en) | 2021-02-24 |
EP3744733A2 (en) | 2020-12-02 |
EP3560956A2 (en) | 2019-10-30 |
US20200308271A1 (en) | 2020-10-01 |
EP3560956A3 (en) | 2020-01-01 |
JP2020172508A (ja) | 2020-10-22 |
EP3974451A2 (en) | 2022-03-30 |
CA3018794A1 (en) | 2017-10-19 |
JP6728392B2 (ja) | 2020-07-22 |
US20170298126A1 (en) | 2017-10-19 |
AU2017250583A1 (en) | 2018-08-16 |
JP2019511532A (ja) | 2019-04-25 |
EP3974451A3 (en) | 2022-07-06 |
WO2017180821A1 (en) | 2017-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022006573A (es) | Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias. | |
MX2018006973A (es) | Anticuerpos anti-cd73 humanizados. | |
PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
PH12016502586A1 (en) | Lipid comprising docosapentaenoic acid | |
PH12018500578A1 (en) | Methods of treating inflammatory diseases | |
MX2017008412A (es) | Productos farmaceuticos y composiciones liquidas estables de anticuerpos contra il-17. | |
MX2020006365A (es) | Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14). | |
GEP20227382B (en) | Anti-coagulation factor xi antibodies | |
MY193175A (en) | Apremilast pharmaceutical compositions | |
MX2018000917A (es) | Acero de alta resistencia con limite minimo de elasticidad elevado y procedimiento para la produccion de un acero de este tipo. | |
IL268007A (en) | Anti-TNF antibodies, preparations and methods for the treatment of active psoriatic arthritis | |
MY195000A (en) | Method for the treatment of neurological disease | |
CR20180002A (es) | Agentes, usos y métodos para el tratamiento | |
NZ733454A (en) | Treatment of autoimmune disorders with cd154 antibodies | |
PH12020551791A1 (en) | Methods for the production of methacrylates | |
MX2018012410A (es) | Metodos para tratar enfermedades inflamatorias. | |
MX2022009380A (es) | Metodos de tratamiento con anticuerpos anti interleucina 17a/17f (il-17a/f). | |
MX2019004182A (es) | Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al. | |
EA201692482A1 (ru) | Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) | |
NZ724772A (en) | Antibodies against hpa-1a | |
MX2022006145A (es) | Anticuerpos trem2 y usos de estos. | |
WO2018071504A3 (en) | Methods of treating diseases with il-23a antibody | |
MX2019010060A (es) | Composiciones y metodo para tratar cancer. | |
MX2017013156A (es) | Metodos para tratar enfermedades. | |
MX2017003014A (es) | Anticuerpos anti-alfa v beta 5 humanizados y usos de estos. |